What is the equity of Globeimmune this year?
Globeimmune has equity of 0 USD this year.
Globeimmune Equity 2024
Globeimmune Equity
0 USD
Ticker
GBIM
ISIN
US37957B1008
WKN
A1J41J
In 2024, Globeimmune's equity was 0 USD, a 0% increase from the 0 USD equity in the previous year.
Globeimmune Aktienanalyse
What does Globeimmune do?
Globeimmune Inc. is a biopharmaceutical company that focuses on the development of immunotherapies for various types of cancer. The company was founded in 1998 in Louisville, Colorado, USA, and went public in 2014. Globeimmune's business model revolves around the use of its patented Tarmogen technology, which aims to activate the immune system against cancer cells. The company has conducted clinical studies for its treatments targeting pancreatic, lung, and prostate cancer. Globeimmune has also formed partnerships with other pharmaceutical companies, including one with Sanko Junyaku in Japan to market its Tarmogen technology in Asia. The company's product range includes various immunotherapies based on the Tarmogen technology, such as GI-4000 for pancreatic cancer, GI-6207 for prostate cancer, and GI-6301 for lung cancer. Globeimmune has achieved success in recent years, including completing a financing round of $15.6 million in 2012 and going public with a $35 million IPO in 2014. Overall, Globeimmune is a promising biopharmaceutical company that focuses on developing effective immunotherapies for cancer patients using its Tarmogen technology, which has the potential to revolutionize cancer treatment and provide patients with effective and gentle therapies. Globeimmune ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Globeimmune's Equity
Globeimmune's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Globeimmune's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Globeimmune's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Globeimmune's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Globeimmune’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Globeimmune stock
What was the equity of Globeimmune compared to the previous year?
The equity of Globeimmune has increased/decreased by 0% decreased compared to the previous year.
What impact does a high equity have on investors of Globeimmune?
A high equity is advantageous for investors of Globeimmune as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Globeimmune?
A low equity can be a risk for investors of Globeimmune, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Globeimmune affect the company?
An increase in equity of Globeimmune can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Globeimmune affect the company?
A reduction in equity of Globeimmune can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Globeimmune?
Some factors that can affect the equity of Globeimmune include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Globeimmune so important for investors?
The equity of Globeimmune is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Globeimmune take to change the equity?
To change equity, Globeimmune can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Globeimmune pay?
Over the past 12 months, Globeimmune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Globeimmune is expected to pay a dividend of 0 USD.
What is the dividend yield of Globeimmune?
The current dividend yield of Globeimmune is .
When does Globeimmune pay dividends?
Globeimmune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Globeimmune?
Globeimmune paid dividends every year for the past 0 years.
What is the dividend of Globeimmune?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Globeimmune located?
Globeimmune is assigned to the 'Health' sector.
Wann musste ich die Aktien von Globeimmune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Globeimmune from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did Globeimmune pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of Globeimmune in the year 2023?
In the year 2023, Globeimmune distributed 0 USD as dividends.
In which currency does Globeimmune pay out the dividend?
The dividends of Globeimmune are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Globeimmune
Our stock analysis for Globeimmune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Globeimmune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
